Intravenous Infusions (XGHA:IIL) Research & Development: GHS Mil (TTM As of . 20)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Intravenous Infusions Research & Development?

Intravenous Infusions XGHA:IIL +8.86% Research & Development is GHS Mil as of . 20.

Research & Development is the aggregate amount of research and development expenses during the year. Intravenous Infusions's Research & Development for the six months ended in . 20 was GHS0.00 Mil. Intravenous Infusions does not have enough years/quarters to calculate the Research & Development for the trailing twelve months (TTM) ended in . 20.

Intravenous Infusions  (XGHA:IIL) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Intravenous Infusions Research & Development Related Terms

Intravenous Infusions Research & Development Historical Data

* Premium members only.

The historical data trend for Intravenous Infusions's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Intravenous Infusions Research & Development Chart

Intravenous Infusions Annual Data
Trend
Research & Development

Intravenous Infusions Semi-Annual Data
Research & Development

Intravenous Infusions Research & Development Calculation

This is the expense the company spent on research and development.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of GHS Mil mean?
Intravenous Infusions (XGHA:IIL) has a Research & Development of GHS Mil as of . 20. Research and development expense is the total cost for research and development activities. View historical data on Intravenous Infusions and its competitors.
Is Intravenous Infusions' Research & Development too high?
Intravenous Infusions' current Research & Development is GHS Mil.
How does Intravenous Infusions' Research & Development compare to PTLF and PCYN?
Intravenous Infusions' Research & Development of GHS Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Intravenous Infusions and its competitors. Intravenous Infusions's current Research & Development is GHS Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Intravenous Infusions stock overvalued right now?
Intravenous Infusions (XGHA:IIL) has a current Research & Development of GHS Mil. The current Research & Development is GHS Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Intravenous Infusions (XGHA:IIL), the current Research & Development is GHS Mil as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Intravenous Infusions Business Description

Address Plot 4/7 Blk L, P.O Box KF 63, Effiduase-Koforidua, GHA
Intravenous Infusions Ltd engages in the production of intravenous infusion and small-volume injectables for therapeutic purposes. The product categories are IV fluids, giving sets, and small-volume injectables. The company earns a majority of its revenue from IV fluids. Some of the IV fluids are sodium chloride solutions, dextrose solutions, dextrose saline solutions, and dextran solutions. Small-volume injectables include pethidine injection, magnesium sulphate injection, and quinine injection. Giving sets include plain giving sets, and blood giving sets.